Potential Target for Cardiac Fibrosis Treatment Identified

by Iswarya on  September 18, 2019 at 11:05 AM Heart Disease News
RSS Email Print This Page Comment bookmark
Font : A-A+

New study identified a potential target for treating heart failure associated with fibrosis. The study looked at an epigenetic 'reader' protein known as BRD4, revealing that it serves a central role in regulating the activation of cardiac fibroblasts. They also found that chemical inhibitors of BRD4 potently hinder cardiac fibroblast activation. The findings of the study are published in the journal Circulation Research.
Potential Target for Cardiac Fibrosis Treatment Identified
Potential Target for Cardiac Fibrosis Treatment Identified

Fibrosis is a wound-healing response after tissue injury or stress. Fibrosis is driven by cells called fibroblasts, which produce excessive amounts of extracellular matrix proteins such as collagen and thereby disrupt the operation of the heart.

Show Full Article


The CU-led team's study looked at an epigenetic 'reader' protein known as BRD4, showing that it serves a central role in regulating the activation of cardiac fibroblasts. They also found that chemical inhibitors of BRD4 potently block cardiac fibroblast activation, providing a foundation for developing BRD4-targeted small molecule therapies for the treatment of heart failure.

The study was published online last week and appeared in the current issue of Circulation Research, the official journal of the American Heart Association and its Council on Basic Cardiovascular Sciences. The cover image for this issue of the journal was chosen from the article. The first authors are Matthew S. Stratton, Ph.D., and Rushita A. Bagchi, Ph.D., and the senior author is Timothy A. McKinsey, PhD.

"Our study enhances the understanding of the molecular mechanisms by which BRD4 controls pathogenic gene expression in fibroblasts," said Bagchi, who is a postdoctoral fellow in the McKinsey laboratory.

"Together with forthcoming findings, this knowledge should yield a cumulative framework that guides the development of more selective BRD4 inhibitors and offers the potential to provide a therapeutic window for the treatment of chronic fibrotic diseases."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive